doi: 10.1038/302716a0 22 MojsovSHeinrichGWilsonIBRavazzolaMOrciLHabenerJF
No Pain, No Gain The main ETFs in the weight-loss drug segment are the Tema Cardiovascular and Metabolic ETF (HRTS), the Roundhill GLP-1 and Weight Loss ETF (OZEM) and Amplify Weight Loss Drug & Treatment ETF (THNR)
It acts on two hormone receptors: GLP and glucose-dependent insulinotropic polypeptide (GIP)
Thats not where the risk-benefit lies. Given that health insurance wont cover GLP-1s if you arent obese, dont have type 2 diabetes, or arent overweight with cardiovascular disease, the cost can add up for years before you know whether the spend was really worth it
This and additional information can be found in the Funds prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com
Katada, S., Yanagimoto, A., Matsui, Y., Hibi, M., Osaki, N., Kobayashi, S., & Katsuragi, Y